ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

vonoprazan

Also written as “TAK-438”, “Vonoprazan” and “Vonoprazan (Reference)”.

Its studies are mostly in Esophagitis · Stomach Ulcer · Gastroesophageal Reflux · Heartburn · Duodenal Ulcer, led by 5 companies.

Drug pageVonoprazan: every studyMany companies study it; this page follows only the 48 they lead. All 100 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Feb 8, 201648 company-led studies, 2 open or runningNext primary completion: Oct 20, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Takeda310 open or runningphase 4since Feb 8, 2016Sep 16, 2011none ahead
Phathom Pharmaceuticalsits history only142 open or runningphase 3since Oct 10, 2019Oct 10, 2019Oct 20, 2027phase 3 · NCT07752407
Genuine Research Center, Egyptits history only10 open or runningphase 1since Nov 14, 2021Nov 14, 2021none ahead
Hanlim Pharm.its history only10 open or runningphase 1since Oct 14, 2024Oct 14, 2024none ahead
Humanis Saglık Anonim Sirketiits history only10 open or runningphase 1since Dec 9, 2025Dec 9, 2025none ahead

Also a collaborator on its studies: Richmond Pharmacology.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 13 studies since Sep 16, 2011.

  1. Jun 26, 2012Phase 3 study in Erosive EsophagitisNCT01630746 · 19 enrolled · Japan
  2. Apr 24, 20142 phase 1 studiesNCT02123953, NCT02123927
  3. May 15, 20142 phase 1 studiesNCT02141711, NCT02141698
  4. Mar 9, 20152 phase 3 studies in Erosive EsophagitisNCT02388737, NCT02388724
  5. Feb 8, 2016Phase 4 study in EsophagitisNCT02679508 · 208 enrolled · Japan
  6. May 13, 2016Phase 1 study in Healthy VolunteersNCT02774902 · 16 enrolled
  7. Sep 2, 2016Phase 1 study in Helicobacter PyloriNCT02892409 · 30 enrolled · Korea, Republic of
  8. Nov 1, 2016Phase 3 study in Non-erosive Gastroesophageal Reflux DiseaseNCT02954848 · 484 enrolled · Japan
  9. Feb 8, 20172 phase 3 studiesNCT03050359, NCT03050307
  10. Mar 16, 2017Phase 1 study in Healthy ParticipantsNCT03085836 · 33 enrolled · China
  11. Apr 12, 2017Phase 4 study in Esophagitis, PepticNCT03116841 · 3 enrolled · Japan
  12. Jan 16, 2019Phase 1 study in Japanese Healthy Adult MaleNCT03808493 · 48 enrolled · Japan
  13. Dec 12, 2019Phase 3 study in Helicobacter PyloriNCT04198363 · 510 enrolled · China
  14. Feb 12, 2021Phase 1 study in Helicobacter PyloriNCT04753437 · 44 enrolled · China

TargetBeta

ATP4A →ATP4B →read by rule
“Potassium-transporting ATPase inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
EsomeprazoleruleAstraZenecaphase 4129
RabeprazoleruleEisaiphase 466
OmeprazoleruleAstraZenecaphase 456
tegoprazanruleHK inno.Nphase 448
fexuprazanruleDaewoong Pharmaceuticalphase 429

Studies

All 31 Takeda leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04753437Helicobacter Pylori · China1CompletedSep 27, 202144
NCT04198363Helicobacter Pylori · China3CompletedNov 1, 2021510
NCT03808493Japanese Healthy Adult Male · Japan1CompletedMar 12, 201948
NCT03116841Esophagitis, Peptic · Japan4CompletedDec 20, 20173
NCT03085836Healthy Participants · China1CompletedAug 17, 201733
NCT03050359Duodenal Ulcer · China, Korea, Republic of, Philippines and more3CompletedMar 19, 2019533
NCT03050307Stomach Ulcer · China, Korea, Republic of, Philippines and more3CompletedFeb 19, 2020234
NCT02954848Non-erosive Gastroesophageal Reflux Disease · Japan3CompletedFeb 25, 2018484
NCT02892409Helicobacter Pylori · Korea, Republic of1CompletedApr 17, 201730
NCT02774902Healthy Volunteers1CompletedSep 201016
NCT02679508Esophagitis · Japan4CompletedMar 5, 2022208
NCT02388737Erosive Esophagitis · China, Korea, Republic of, Malaysia and more3CompletedDec 24, 2018703
NCT02388724Erosive Esophagitis · China, Korea, Republic of, Malaysia and more3CompletedJul 27, 2017481
NCT02141711Gastroesophageal Reflux · United Kingdom1CompletedFeb 200948
NCT02141698Dose Finding Study1CompletedFeb 200873
NCT02123953Dose Finding Study1CompletedMar 200960
NCT02123927Ascending Single Dose Study1CompletedDec 2007108
NCT01630746Erosive Esophagitis · Japan3CompletedSep 201319
NCT01568398Stomach Ulcer · Japan3CompletedAug 201327
NCT01568385Stomach Ulcer · Japan3CompletedSep 201330
NCT01505127H. Pylori Infection · Japan3CompletedJun 2013650
NCT01474369Non-erosive Gastroesophageal Reflux Disease · Japan3CompletedFeb 2013827
NCT01459367Erosive Esophagitis · Japan3CompletedMar 2013607
NCT01456260Stomach Ulcer · Japan3Completed406
NCT01456247Stomach Ulcer · Japan3CompletedOct 2013439
NCT01452776Erosive Esophagitis · Japan3CompletedJul 2013305
NCT01452763Stomach Ulcer · Japan3CompletedApr 2013621
NCT01452750Stomach Ulcer · Japan3CompletedJun 2013642
NCT01452724Duodenal Ulcer · Japan3CompletedFeb 2013372
NCT01452711Stomach Ulcer · Japan3CompletedDec 2012482
NCT01452698Erosive Esophagitis · Japan3CompletedAug 2012409

How it is read

Names in the registry

  • “TAK-438”, 32 entries
  • “Vonoprazan”, 20 entries
  • “Vonoprazan (Reference)”, 1 entry
  • “Vonoprazan Tablets”, 1 entry
  • “VOQUEZNA® Tablets”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.